Multitumor | Genomic Assays in the “Real” Oncology World — Part 2: Exploring the Role of Genomic Testing in Guiding Treatment for Patients with Advanced Breast, Colorectal and Prostate Cancers
Genomic Assays in the “Real” Oncology World — Part 2: Genomic
Assays in Prostate and Breast Cancer — Featuring a roundtable
discussion with Drs Emmanuel S Antonarakis, Johanna Bendell, Ian E
Krop and Andrew McKenzie.
NGS for Metastatic Prostate Cancer (mPC) and the
Potential Clinical Significance of Genomic
Alterations
Genetic alterations assessed in routine practice, including MSI
status, BRCA mutations and AR-V7 variants; role of multiplex
testing
Presentation (Dr Antonarakis): Biomarker
assessment in mPC; detection of DNA damage repair abnormalities and
prediction of benefit with PARP and PD-1 inhibitors
Landscape of DNA damage repair mutations in newly diagnosed and
metastatic prostate cancer
Rationale for the use of PARP inhibitors for prostate cancer
with BRCA or ATM mutations
Genetic testing of primary and metastatic tumors for
alterations in the DNA repair and androgen receptor (AR) signaling
pathways
Clinical significance and genetic detection of AR splice
variants
Results of the CARD trial: Cabazitaxel versus enzalutamide or
abiraterone for patients with mCRPC previously treated with
docetaxel who experience rapid disease progression on an
AR-targeted agent
Efficacy of olaparib for mCRPC
Available data with rucaparib, niraparib and talazoparib for
mCRPC
Role of radium-223 dichloride for patients with mPC; novel
combination approaches with radium-223 under investigation
Sensitivity of BRCA1, BRCA2 and ATM mutations to PARP
inhibitors
Activity of PARP inhibitors in patients with breast, ovarian,
prostate and pancreatic cancers with BRCA mutations
Homologous recombination deficiency and response to PARP
inhibitors
Case (Dr Antonarakis): A man in his mid-40s
with mCRPC and a BRCA2 mutation attains a complete response to
olaparib
Case (Dr Antonarakis): A man in his mid-60s
diagnosed with de novo mPC and MSI-high status, high tumor mutation
burden and an MSH2 mutation experiences an excellent response to
pembrolizumab after multiple lines of therapy
Association of ductal and intraductal prostate cancer with a
high prevalence of DNA damage repair gene mutations
Predictors of benefit with immune checkpoint inhibitors
Multigene Testing and Detection of Genomic Alterations
in Metastatic Breast Cancer (mBC)
Role of MSI testing and multiplex genomic assays in mBC
Assessment of PIK3CA and BRCA mutations and assays for
ESR1
Presentation (Dr Krop): Biomarker assessment
in mBC — ER-positive and triple-negative disease
PTEN loss and implications for therapeutic decision-making for
mBC
ESR1 mutations and resistance to hormone therapy
Efficacy of PARP inhibitors in patients with BRCA
mutations
HER2 expression in HER2 nonamplified cancers; activity of
trastuzumab deruxtecan in HER2-low breast cancer
PD-L1 and other biomarkers predictive of benefit from
immunotherapy in triple-negative breast cancer (TNBC)
Case (Dr Krop): A woman in her late 50s with
de novo TNBC receives atezolizumab/nab paclitaxel as
first-line therapy
Case (Dr Krop): A woman in her early 60s with
ER-positive, HER2-negative mBC and a germline BRCA2 mutation whose
disease progresses through multiple therapies attains a partial
response to olaparib
The Sarah Cannon Experience with Molecular Tumor
Boards
The use of molecular tumor boards to review molecular profiling
data and facilitate therapeutic decision-making
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.